Proactive Investors - Run By Investors For Investors

Biocept rises after announcing expansion of pathology partnership platform

The molecular-diagnostics company says its EmpowerTC platform now offers pathologists the ability to analyze prognostic and predictive markers on circulating tumor cells from a liquid biopsy using immunocytochemistry methods
A medical examination room
The company says its pathology partnership platform distinguishes it from other services

Biocept Inc (NASDAQ:BIOC) advanced Wednesday after announcing that it expand its pathology partnership platform.

The molecular-diagnostics company said its EmpowerTC platform now offers pathologists the ability to analyze prognostic and predictive markers on circulating tumor cells  from a liquid biopsy using immunocytochemistry methods.

Shares of Biocept rose 2.9% to US$1.22 in Wednesday’s Nasdaq trading.

READ: Biocept rallies after announcing Dubai company will validate patented liquid biopsy technology

The new offering, in addition to an expanded biomarker menu, supplements the previous capabilities of Biocept's proprietary pathology partnership platform to analyze liquid biopsy biomarkers using fluorescence in situ hybridization (FISH) methods.

“We believe that our pathology partnership platform distinguishes Biocept from other liquid biopsy services, and we plan to continue to innovate and launch additional markers to expand this service further in the future,” Biocept Chief Commercial Officer Edwin Hendrick said in a statement.

Last month, Biocept announced an agreement under which a Dubai company will validate its patented liquid biopsy technology in order to perform testing for the detection of tumor biomarkers. 

Contact Dennis Fitzgerald at [email protected]

View full BIOC profile View Profile

Biocept Inc Timeline

Related Articles

Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
1542204301_heart.jpg
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use